AcuCort’s drug Zeqmelit® registered as a trademark in the USA

AcuCort AB announces that the company’s drug Zeqmelit® has been registered as a trademark in the USA.

The trademark protection is strategically important for the company’s commercialization phase. The USA is both the world's largest individual pharmaceutical market and AcuCort’s most important market. 

– It is very positive that we have now received trademark protection for our oral film Zeqmelit® with associated applications in the USA. The trademark protection is an important step towards our upcoming commercialization phase in the USA. Furthermore, we look forward to launching Zeqmelit® in the Nordic countries starting from September 1, says AcuCort’s CEO Jonas Jönmark.

The trademark registration has been issued by the United States Patent and Trademark Office (USPTO) and is valid for 10 years and can thereafter be renewed.
Zeqmelit® has been registered as a trademark in all member states of the European Union as well as in Norway, the United Kingdom, Switzerland, Australia, India, Israel, China, Japan, and now in the USA.

For further information: 
Jonas Jönmark, vd, AcuCort AB
Tel: +46 70 365 5400
Email: jonas.jonmark@acucort.se

About AcuCort AB (publ)
AcuCort has developed and is commercializing Zeqmelit®, a new rapidly dissolving oral film placed on the tongue, based on the well-known cortisone substance dexamethasone. The drug is a smart product in a new, innovative, patented, and user-friendly administration form primarily for the treatment of severe and acute allergic reactions, croup in children, nausea and vomiting during chemotherapy, and for the treatment of patients with COVID-19 requiring supplemental oxygen therapy. Zeqmelit® is approved in Sweden, Denmark, Norway, and Finland. AcuCort (ticker: ACUC) is listed on the Spotlight Stock Market. Visit www.acucort.se for more information.